成功应用 Crizanlizumab 治疗 SCD 相关性阴茎异常勃起：病例系列研究。

Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series.

机构信息

Department of Internal Medicine, John P. and Kathrine G. McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

出版信息

J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231191873. doi: 10.1177/23247096231191873.

DOI:10.1177/23247096231191873

PMID:37731262

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10515560/

Abstract

Priapism, an unwanted, painful, prolonged erection that is unrelated to sexual stimulation, is a common complication of sickle cell disease (SCD). Priapic events in SCD are stuttering, meaning they occur repeatedly with intervening periods of detumescence. Without health care intervention, repeated episodes can lead to erectile dysfunction. There are limited treatment options for SCD-related priapism and no approved targeted therapies. Crizanlizumab is a monoclonal antibody that binds to P-selectin and is used to reduce the frequency of vaso-occlusive crises in patients with SCD. Here, we report the cases of 3 patients with SCD-related priapism who were treated with crizanlizumab. All patients were African American men who experienced numerous priapic episodes that interfered with their daily lives. Upon treatment with crizanlizumab, priapic events were reduced in all 3 patients. These successful cases suggest a potential role for crizanlizumab in the prevention of SCD-related priapism.

摘要

阴茎异常勃起是一种不想要的、疼痛的、长时间的勃起，与性刺激无关，是镰状细胞病（SCD）的常见并发症。SCD 中的阴茎异常勃起是间歇性的，这意味着它们会反复出现，伴有勃起消退期。如果没有医疗保健干预，反复发作可能会导致勃起功能障碍。SCD 相关的阴茎异常勃起的治疗选择有限，也没有批准的靶向治疗方法。Crizanlizumab 是一种单克隆抗体，可与 P 选择素结合，用于减少 SCD 患者血管阻塞性危象的发生频率。在这里，我们报告了 3 例 SCD 相关阴茎异常勃起患者接受 crizanlizumab 治疗的病例。所有患者均为非裔美国男性，经历了多次影响日常生活的阴茎异常勃起。接受 crizanlizumab 治疗后，3 例患者的阴茎异常勃起事件均减少。这些成功的病例表明 crizanlizumab 在预防 SCD 相关阴茎异常勃起方面可能具有一定作用。